AI Article Synopsis
- In this study, new thiazole derivatives were created and tested for their anticancer effects on different cancer cell lines (MCF-7, A549, and NIH/3T3) using techniques like the MTT method and flow cytometry.
- One specific compound with a 4-methoxyphenyl group showed the most significant anti-tumor effect against the MCF-7 cell line, indicating high DNA synthesis inhibition and increased apoptosis rates.
- Additionally, compounds with 4-bromo, 4-chloro, and 4-fluorophenyl groups demonstrated strong apoptosis in the A549 cell line at lower concentrations compared to cisplatin, and one compound also exhibited notable anticholinesterase activity with
Article Abstract
In this study, novel '-(3-cyclohexyl/phenyl-4-(substituted phenyl)thiazole-2(3)-ylidene)-2-[(5,6,7,8-tetrahydronaphthalen-2-yl)oxy]acetohydrazide (-) derivatives were synthesized and their anticancer potency were evaluated on human breast adenocarcinoma cell line (MCF-7), human lung carcinoma cell line (A549) and mouse embryoblast cell line (NIH/3T3) using the MTT method, DNA synthesis inhibition and flow cytometric analysis. Compound bearing 4-methoxyphenyl moiety exhibited the highest antitumor efficiency against MCF-7 cell line with higher DNA synthesis inhibition and apoptotic cell percentages (ealy+late apoptotic cell). On the other hand, compounds , , and bearing 4-bromo, 4-chloro and 4-florophenyl moieties, respectively caused excellent apoptosis levels against A549 cell line when treated with lower concentration even than cisplatin. Anticholinesterase activity of the compounds were also tested, compound showed 49.92% inhibition of acetylcholinesterase (AChE).
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6017121 | PMC |
| http://dx.doi.org/10.3390/molecules23010135 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!